Bausch Health Companies Inc. develops, manufactures, and markets pharmaceutical, medical device, and over-the-counter products primarily in eye health, gastroenterology, and dermatology. Its operations are divided into five segments: Bausch + Lomb (approximately 40% of revenue), Salix (about 20%), International Rx (around 25%), Ortho Dermatologics (approximately 10%), and Diversified Products (about 5%). The company serves healthcare providers, hospitals, and consumers. Factors supporting its endurance include a diverse product portfolio and established brands, while challenges may arise from regulatory pressures and competition in the pharmaceutical industry.
—
Bausch Health Companies Inc. develops, manufactures, and markets pharmaceutical, medical device, and over-the-counter products primarily in eye health, gastroenterology, and dermatology. Its operations are divided into five segments: Bausch + Lomb (approximately 40% of revenue), Salix (about 20%), International Rx (around 25%), Ortho Dermatologics (approximately 10%), and Diversified Products (about 5%). The company serves healthcare providers, hospitals, and consumers. Factors supporting its endurance include a diverse product portfolio and established brands, while challenges may arise from regulatory pressures and competition in the pharmaceutical industry.
—
Daily adjusted close
Bausch Health Companies Inc. develops, manufactures, and markets pharmaceutical, medical device, and over-the-counter products primarily in eye health, gastroenterology, and dermatology. Its operations are divided into five segments: Bausch + Lomb (approximately 40% of revenue), Salix (about 20%), International Rx (around 25%), Ortho Dermatologics (approximately 10%), and Diversified Products (about 5%). The company serves healthcare providers, hospitals, and consumers. Factors supporting its endurance include a diverse product portfolio and established brands, while challenges may arise from regulatory pressures and competition in the pharmaceutical industry.